The European Union Drugs Agency (EUDA) is the leading authority on illicit drugs in Europe. Based in Lisbon, Portugal, the EUDA provides independent scientific evidence and analysis on all aspects of this constantly changing threat to individual lives and wider society. The EUDA contributes to EU and national policies to protect Europe's citizens from drug-related harms. It is an agency of the European Union.
Our new mission focuses on contributing to European Union (EU) preparedness on drugs through four main actions: anticipate, alert, respond, and learn.
The EMCDDA is offering a series of webinars around the theme of COVID-19. The purpose of the webinars is to help those working in the drugs field understand how drug users, and those supporting them, are coping with the pandemic and to share knowledge and experience. The webinars will give a voice to key professionals working in the drugs field and will allow for a panel discussion on emerging challenges.
The most recent report of the European School Survey Project on Alcohol and Other Drugs (ESPAD) will be published on 12 November 2020. The ESPAD Report 2019 is based on a 2019 survey in 35 Europen countries. ESPAD has been collecting data through school surveys every four years since 1995. Further iinformation is available on the ESPAD website.
How is the COVID-19 pandemic affecting drug use, supply and services? What are the health costs of drug use in Europe today? What do the latest data tell us about drug production and trafficking trends? Be the first to know when the EU drugs agency (EMCDDA) launches its European Drug Report 2020: Trends and Developments in a live online media event on 22 September.
Background: this is the 6th EMCDDA webinar on the Coronavirus. It will be exploring with the help of three experts from Northern, Central, Southern European EU countries (Finland, Greece and The Netherlands) whether the COVID-19 related emergency is having or is going to have any impact on Drugs Policy.
This is the fourth EMCDDA webinar on the coronavirus and will be based on a recent Trendspotter exercise on drug use.
A conversation with:
